This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Ovarian Cancer
  • /
  • Adavosertib plus gemcitabine for platinum-resistan...
Journal

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Read time: 2 mins
Published:22nd Jan 2021
Author: Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G et al.
Source: The Lancet
Availability: Pay for access, or by subscription
Ref.:Lancet. 2021 Jan 23;397(10271):281-292.
DOI:10.1016/S0140-6736(20)32554-X
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest